Martin Shkreli is an American former hedge fund manager and convicted felon.

Shkreli is the co-founder of the hedge funds;

1. Elea Capital,
2. MSMB Capital Management and
3. MSMB Healthcare; the co-founder and former chief executive officer (CEO) of the pharmaceutical firms Retrophin and Turing Pharmaceuticals (now Vyera Pharmaceuticals); and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

In September 2015, Shkreli was widely criticized when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by a factor of 56 (from US$13.50 to $750 per pill).

In 2017, Shkreli was charged and convicted in federal court on two counts of securities fraud and one count of conspiring to commit securities fraud, unrelated to the Daraprim controversy.

Shkreli was sentenced to seven years in federal prison and up to $7.4 million in fines and in the civil case, he was fined a further $64.6 million to be given to victims nationwide.

Prior to May 2022, Shkreli was held at the low-security federal prison in Allenwood, Pennsylvania, with an expected release date in September 2022.

On May 18, 2022, it was announced that Shkreli had been released early.

According to Shkreli’s lawyer Benjamin Brafman, the decision was made after Shkreli completed “all programmes that allowed for his prison sentence to be shortened”.

Shkreli was moved to a halfway house and will be fully released in September 2022.